key: cord-0793497-y6a9g1lt authors: Ammar, Mahmoud A.; Tran, Lydia J.; McGill, Bryan; Ammar, Abdalla A.; Huynh, Phu; Amin, Nilesh; Guerra, Michael; Rouse, Ginger E.; Lemieux, Diana; McManus, Dayna; Topal, Jeffrey E.; Davis, Matthew W.; Miller, LeeAnn; Yazdi, Marina; Leber, Molly Billstein; Pulk, Rebecca A. title: Pharmacists leadership in a medication shortage response: Illustrative examples from a health system response to the COVID‐19 crisis date: 2021-04-28 journal: J Am Coll Clin Pharm DOI: 10.1002/jac5.1443 sha: 543441f069307ce0cf62b2f4054c77f7d7b4023b doc_id: 793497 cord_uid: y6a9g1lt As medication experts, clinical pharmacists play an active and dynamic role in a medication shortage response. Supplementing existing guidelines with an actionable framework of discrete activities to support effective medication shortage responses can expand the scope of pharmacy practice and improve patient care. Dissemination of best practices and illustrative, networked examples from health systems can support the adoption of innovative solutions. In this descriptive report, we document the translation of published shortage mitigation guidelines into system success through broad pharmacist engagement and the adaption and implementation of targeted strategies. The profound, wide‐reaching medication shortages that accompanied the coronavirus disease 2019 (COVID‐19) pandemic are used to highlight coordinated but distinct practices and how they have been combined to expand the influence of the pharmacy enterprise. Medication shortages pose an ever-present challenge to optimal patient care within the United States. Market, regulatory, and supply chain forces play varied and intertwined roles in the availability of medications. In 2019, the Food and Drug Administration identified 166 new medication shortages, 39% of which involved parenteral products. 1 Each shortage forces providers to rely on second-line or nonstandard therapies, disrupting usual practices and potentially resulting in untoward effects. 2 A retrospective analysis of the 2011 norepinephrine shortage demonstrated significant clinical impact and increased in-hospital septic shock mortality in hospitals unable to source this essential medication. 3 The development of strategies to optimize inventory and acquisition, conserve scarce products, and ensure appropriate utilization are essential safeguards against the ever-present threat of short supply. Health systems must weigh the anticipated duration of the disruption and co-occurring market factors when designing and implementing therapeutic alternatives and process changes to respond to medication shortages effectively. Although shortage mitigation strategies Molly Billstein Leber and Rebecca A. Pulk should be considered joint senior authors. support patient care continuity, they can significantly increase the direct costs of health systems as they acquire alternative therapeutics, compound alternatives, resource the development of revised policies and procedures, and re-educate staff. The coronavirus disease 2019 pandemic has led to an unprecedented number of medication shortages through record demand for essential medications and widespread supply chain disruption. Entire medication classes became scarce during the initial wave of infections and continue to be in short supply, including neuromuscular blockers, sedatives, analgesics, and vasopressors. 4 These products, particularly in injectable form, are foundational to the care provided to all critically ill, mechanically ventilated, and perioperative patients. These profound shortages have not only affected the care of patients infected with COVID-19, they have also impacted the overall health system capacity and, in some cases, delayed the resumption of routine care activities. As medication experts, pharmacists possess comprehensive knowledge of applied therapeutics, insight into medication workflows, and understanding of a shortage's impact. Their leadership can mitigate the untoward effect of medication shortages. Dissemination of pharmacist-driven strategies in a shortage response can promote improved patient care and advancement of the profession. Health systems seeking to mitigate the deleterious effects of medication shortages have access to many foundational published resources. The American Society of Health-System Pharmacists (ASHP) Guideline on managing drug product shortages presents a widely cited response model that describes discrete elements of effective response: identification, parallel operational and clinical assessments, impact analysis, and finalization of a shortage response plan followed by parallel efforts to implement and communicate process changes across the organization. 5 In this model, pharmacists lead the logistical elements of medication shortage response as part of a multidisciplinary team from which clinical strategy emerges. 5 There is little published guidance detailing discrete strategies to position pharmacists to accelerate an effective shortage response. Literature reporting the impact of pharmacist leadership within shortage response efforts has primarily focused on operational optimization, drug use policy creation, and educational efforts. [5] [6] [7] [8] [9] [10] [11] Site-specific reports have described mechanisms by which pharmacy technicians and students can serve as team extenders to mitigate the effects of medication shortages in alignment with well-described practice advancement initiatives. 12 Dissemination of successful implementations can catalyze change and accelerate pharmacists' advancement. Yale New Haven Health (YNHH) is a multi-hospital academic health system located along the Connecticut shoreline comprised of four delivery networks spanning from the New York border into Rhode Island with 2475 total beds. In 2012, YNHH began to consolidate and systematize its response to medication shortages across all inpatient sites. Broad approval of an aligned, dynamic approach to shortage mitigation was garnered in 2017 and allowed for coordinated management of limited resources to minimize patient harm. This oversight system has continued to expand through iterative improvements over the past 3 years. YNHH has adapted the American Society of Health-System Pharmacists (ASHP) medication shortage response guidance to meet system needs, reframing and adjusting the workflow described in the broad guidance into a framework consisting of five distinct phases that temporally overlap and create an iterative cycle to meet system needs ( Figure 1 ). The described system has emerged through an iterative process, guided by Lean methodology and established implementation frameworks. [13] [14] [15] [16] The first phase, identification, integrates operational assessment and impact analysis to support a robust understanding of the pending medication shortage and the projected disruption within our health system. The second phase evaluates therapeutic alternatives from a clinical perspective, incorporating operational insights into proposed solutions. Once a potential alternative is identified, key clinical stakeholders are engaged to develop buy-in and obtain endorsement and official ratification when needed. Implementation of accepted strategies involves developing messaging and decision support tools in the electronic medical record (EMR), education efforts to ensure clinical team awareness, and integrating active clinical workflows. Once a shortage has been managed, effort shifts to ensuring system sustainability by monitoring real-time use, refining management strategies, and building system capacity by incorporating any learnings or efficiencies gained into standard operating procedures. 17 Throughout each of these five phases, clinical specialists and unit-based pharmacists engage in discrete actions that support the clinical, administrative, and operational success of shortage mitigation In this report, we seek to document and disseminate many of the discrete steps taken by clinical pharmacists within YNHH that support our system's ability to rapidly and successfully navigate medication F I G U R E 2 Operational and clinical activities across each phase of a medication shortage response. Throughout each phase of a medication shortage response, pharmacists are positioned to impact clinical, administrative, logistical, and operational success of a health system. P&T, Pharmacy and Therapeutics committee shortages to support the broader adaptation of actionable strategies and promote practice advancement. At shortage identification, clinical pharmacists rapidly articulate the current use of affected products and quantify medication needs. Profound shortages across many injectable opioid products threatened our system's ability to address patient pain adequately. Quantification of average daily and weekly intravenous opioid use throughout the system allowed for the expression of therapeutic need in morphine equivalents. Use of a normalized measure of analgesic burn rate allowed for rapid evaluation of all available alternatives. Remifentanil, an agent previously reserved for use by anesthesiology providers, was identified as a viable therapeutic alternative that could ensure effective pain control in critically ill patients. 18, 19 Engaging pharmacists across multiple practice settings ensured a In preparation of the anticipated surge, clinical pharmacy specialists from infectious diseases, critical care, internal medicine, and cardiology were tasked to define pharmacotherapies that could improve the care of patients presenting with COVID-19. The initial list of COVID-19 essential medications contained antibiotics, potential antivirals, analgesics, immunologic therapies, respiratory treatment, and medications used in critical care such as sedatives and vasopressors. As our COVID-19 census increased, pharmacists quickly identified additional medications such as acetaminophen, neuromuscular blockers, sedatives, eye lubricants, and agents that control secretions. The recognition of an increased incidence of thrombotic complications within patients infected with COVID-19 prompted the addition of anticoagulant agents. As clinical experience revealed that antibiotics, specific antivirals, and inhaled medications (outside of albuterol) did not play a critical role in treating COVID-19, these products were removed. Knowledge of dosing and medication use practices allowed pharmacists to articulate medication use in a manner that ensured anticipatory ordering or alternative planning. Critical care pharmacists leveraged their experience caring for previous patients with acute respiratory distress syndrome to estimate the daily neuromuscular blocker guidelines were developed for the use of atracurium in case the supply of cisatracurium was insufficient despite restrictions. 23 A single agent shortage may extend to additional medications within the same class as hospitals turn to alternatives. Due to a combination of manufacturing delays and a substantial increase in usage, widespread sedative shortages occurred with propofol, and later, lorazepam and midazolam, necessitating the use of all available alternatives. 4 Clinical pharmacists first identified that dexmedetomidine could be used preferentially in patients for light sedation and not in those that required deep sedation. This allowed continuous infusion benzodiazepines to be reserved for patients who required deep sedation or those who experienced hypertriglyceridemia while on propofol. 24 When it became apparent that benzodiazepines, particularly lorazepam, were in short supply, pharmacists performed a literature review to identify alternative agents that could be used in place of benzodiazepines for conditions other than ICU sedation. This review identified phenobarbital as a safe and effective option for the treatment of alcohol withdrawal in lieu of benzodiazepines. 25 The review also identified alternative anti-epileptic medications that could be utilized to manage alcohol withdrawal as an adjunct to decrease benzodiazepine usage. 26 Engaging pharmacists to promote the use of enteral and transdermal alternatives to parenteral therapy has been well reported as an impactful medication intervention and proved an effective means of conserving critical medication supply during shortages of parenteral potassium products. 27 To conserve injectable opioid supply during the COVID-19 surge, pharmacists identified and promoted three previously reported strategies to replace continuous opioid infusions with enteral oxycodone, enteral methadone, and transdermal fentanyl in patients tolerating an oral diet. [28] [29] [30] [31] Restricting medications to patients meeting specific criteria is a standard conservation strategy. During the COVID-19 pandemic, the use of benzodiazepines was restricted to patients who failed to achieve adequate sedation after receiving a high dose of propofol (65 mcg/ kg/min) or not tolerating propofol due to elevated triglyceride levels (>1000 mg/dL). 32 As trusted team members, clinical pharmacists are positioned to engage key stakeholders, identify potential barriers, and propose clinically and operationally sound solutions to ensure the medication shortage's successful navigation. Through their established relationships, pharmacists can identify key physicians, advance care providers, nurses, respiratory therapists, and clinical leadership to aid in the development and review of effective medication-shortage mitigation strategies. During the COVID-19 surge, pharmacists were embedded within the Incident Command Management groups to coordinate the institutional response to pandemic challenges. 17 In addition, our pharmacydriven Antimicrobial Stewardship Team (AST) became vital members of the team founded to actively identify COVID-19 treatment algorithms. These sanctioning bodies enabled accelerated review and approval of medication use guidelines and protocols to mitigate medication shortage during COVID-19. Due to the COVID-19 surge's acuity, proposals approved by these groups were implemented in an expedited manner to meet urgent needs, often within a single day. After implementation, the existing system Pharmacy and Therapeutics (P&T) committee structures completed post-hoc review of these recommendations. were instructed to contact their unit pharmacist to order remifentanil for patients who could not use hydromorphone. An EMR tool was created to alert the pharmacist to potential adverse reactions (ie, triglycerides >500 mg/dL on propofol therapy and liver function test abnormalities for patients on remdesivir) and prioritized interventions for those patients in real-time to ensure safe utilization of alternative or restricted agents. Additional builds to support medication shortages throughout the COVID-19 surge included alternative profiles for phenobarbital and cisatracurium, modified alcohol withdrawal order sets curtailing the use of benzodiazepines, and a COVID-19 specific pharmacist alert for internal pharmacist documentation. As widespread shortages were expected throughout the COVID-19 surge, anticipatory builds of medication profiles were initiated for nonformulary products, and internal identifiers were added for nonstandard products. This deviation from the standard practice of completing these builds in real-time decreased the time needed to switch to alternatives as supplies dwindled. Through the creation of the COVID-19 descriptor within the internal pharmacist documentation system, real-time insight from frontline pharmacists was leveraged to improve a system medication shortage response. Suggestions relating to standard bag sizes, workflows, and challenges were transformed into mitigation strategies. This innovative application of the EMR not only accelerated change, but it also provided an effective mechanism of collecting responses from across the pharmacy team. Once a recommendation to manage a medication shortage has been approved through the aforementioned health system channels, and A weekly live educational meeting for pharmacy enterprise staff provided medication shortage updates and reinforced the information included in the EMR and written announcements. 35 Many lessons learned throughout the COVID-19 response have been integrated into standard health system practice by the pharmacy enterprise. As with many shortages, introducing alternatives and optimizing existing formulary drugs can drive changes to increase efficient medication use. Critical care pharmacists played a vital role in establishing criteria for appropriate use, along with guidance built into our computerized physician order entry system on dosing and administration. This key guidance will remain in place following the resolution of sedative shortages and COVID-19. Historical approval of alternatives to medications in short supply at our health system involved building a consensus among prescriber stakeholders. When implementing alternatives, or restrictions were not deemed urgent, formulary and drug use policy changes were comprehensively reviewed and approved by the P&T committee at each hospital in the health system and the Formulary Integration Committee. However, COVID-19 required expedited review and approval of alternatives via incident command groups. The success of this expedited process has led to a re-evaluation of the role of P&T review. This re-evaluation may result in a sustained expedited review and approval process even after the COVID-19 surge has abated. The COVID-19 pandemic has provided a real-time stress test of the shortage response strategies that have evolved within our system over the past 5 years. This descriptive report details the complement of tactics our pharmacists employ to minimize the impact of medication shortages. Well-laid foundational processes have enhanced our ability to navigate the continually changing supply landscape. Three key organizational factors have facilitated our success: 1. An established framework for accelerated medication use policy approval Having a predefined mechanism to rapidly approve policy changes in light of medication shortages ahead of the COVID-19 surge has allowed our team to focus on executing a response instead of scrambling to implement policy. National drug shortages: Annual new shortages by year The impacts of medication shortages on patient outcomes: A scoping review Association between US norepinephrine shortage and mortality among patients with septic shock ASHP guidelines on managing drug product shortages The drug shortage crisis in the United States: causes, impact, and management strategies Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action Collaborative management strategies for drug shortages in neurocritical care Clinical management strategies and implications for parenteral nutrition drug shortages in adult patients The drug shortage era: a scoping review of the literature Prospective inventory management systems for preempting problems related to medication unavailability Applying contemporary management principles to implementing and evaluating value-added pharmacist services Advancing pharmacy practice through implementation science Effect of lean process improvement techniques on a university hospital inpatient pharmacy Lead-time reduction utilizing lean tools applied to healthcare: The inpatient pharmacy at a local hospital Dynamic pharmacy leadership during the COVID-19 crisis: Optimizing patient care through formulary and drug shortage management Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial A comparison of the remifentanil and fentanyl adverse effect profile in a multicenter phase IV study Formulary evaluation using a class review approach: experience and results from an academic medical center Continuous-infusion neuromuscular blocking agents in critically ill neonates and children Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient Comparison of cisatracurium versus atracurium in early ARDS The pain, agitation, and delirium care bundle: Synergistic benefits of implementing the 2013 Pain, Agitation, and Delirium Guidelines in an integrated and interdisciplinary fashion Patient outcomes associated with phenobarbital use with or without benzodiazepines for alcohol withdrawal syndrome: A systematic review Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders Interventions to improve antibiotic prescribing practices for hospital inpatients Methadone reincarnated: Novel clinical applications with related concerns The use of methadone for cancer pain Multiple risks for patients using the transdermal fentanyl patch A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors The use of neuromuscular blocking agents in the ICU: where are we now? A consensus statement on considerations for a successful CPOE implementation Raising the SBAR: How better communication improves patient outcomes Pharmacists leadership in a medication shortage response: Illustrative examples from a health system response to the COVID-19 crisis The authors declare no conflicts of interest.